Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 is a cancer-testis antigen, a protein expressed in a variety of tumors, including melanoma, synovial sarcoma, and multiple myeloma, but generally not in normal adult tissues, with the exception of testis and placenta. Its restricted expression pattern and demonstrated immunogenicity make it an attractive target for cancer immunotherapy. It is utilized in vaccine formulations to induce antigen-specific humoral and cellular immune responses, and as a target for T-cell receptor (TCR) engineered T-cell therapies, where T cells are genetically modified to recognize and attack NY-ESO-1-expressing cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NY-ESO-1.